Logo

MDBH

MDB Capital Holdings, LLC Class A common

MDBH

MDB Capital Holdings, LLC Class A common • NASDAQ
$3.52 ▲ 3.10% (+0.11)
Market Cap $34.89 M
52w High $7.98
52w Low $3.16
Dividend Yield 0%
P/E 2.46
Volume 146
Outstanding Shares 9.92M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.251M ▲ $5.006M ▲ $-4.657M ▲ -372.279% ▼ $-0.47 ▲ $5.655K ▲
Q2-2025 $0 ▼ $3.573M ▼ $-8.248M ▼ 0% ▲ $-0.83 ▲ $-5.194M ▼
Q1-2025 $2.14M ▲ $3.714M ▲ $-6.587M ▼ -307.786% ▼ $-1.49 ▼ $-4.441M ▼
Q4-2024 $917.222K ▲ $2.889M ▼ $30.917M ▲ 3.371K% ▲ $6.99 ▲ $33.42M ▲
Q3-2024 $0 $3.549M $-7.735M 0% $-0.83 $-8.001M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $15.932M ▼ $61.511M ▼ $1.88M ▲ $59.737M ▼
Q2-2025 $17.092M ▼ $63.518M ▼ $1.734M ▲ $61.89M ▼
Q1-2025 $19.552M ▼ $68.626M ▼ $1.64M ▼ $67.091M ▼
Q4-2024 $20.437M ▲ $71.976M ▲ $1.903M ▼ $70.163M ▲
Q3-2024 $16.679M $34.211M $6.029M $28.997M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.657M ▲ $-1.918M ▲ $-25.677K ▼ $0 $-1.943M ▲ $-1.943M ▲
Q2-2025 $-8.25M ▼ $-2.148M ▼ $0 ▲ $0 $-2.148M ▼ $-2.148M ▼
Q1-2025 $-6.587M ▼ $-267.429K ▲ $-990.426K ▼ $0 ▼ $-1.258M ▼ $-267.43K ▼
Q4-2024 $32.458M ▲ $-417.026K ▲ $2.847M ▲ $587.368K ▲ $3.017M ▲ $229.258K ▲
Q3-2024 $-8.972M $-2.511M $509.799K $-235.89K $-2.238M $-2.437M

Five-Year Company Overview

Income Statement

Income Statement MDBH is still essentially a development-stage platform. Reported revenue is negligible, and the business has operated with recurring operating losses, though the most recent year shows a small accounting profit. That recent profit likely reflects one‑off or structural items rather than a mature, recurring earnings engine. The pattern suggests the company is still investing in building its ecosystem—Public Ventures, PatentVest, and Invizyne—rather than running a scaled, fee-driven capital markets business. Earnings are therefore volatile, not yet a reliable indicator of long‑term profitability, and highly dependent on a small number of transactions and ventures rather than broad, diversified income streams.

Balance Sheet

Balance Sheet The balance sheet is very small and simple, with modest assets, no financial debt, and equity funding the business. The absence of debt reduces financial strain but also underscores that the company is still thinly capitalized relative to its ambitions. Cash levels are positive but not large, indicating a limited cushion to absorb extended periods of investment and operating losses without fresh capital. Overall, MDBH looks like an early-stage platform with a clean but lightweight balance sheet, where future strength will depend on successfully growing asset-light, fee-based activities and crystallizing value in its holdings and subsidiaries.

Cash Flow

Cash Flow Operating cash flow has been consistently negative in recent years, which is typical for a firm building out a new business model and internal capabilities. The company is not consuming cash through heavy capital expenditures, so the burn largely reflects ongoing operating and development costs rather than big physical investments. This pattern highlights the central risk: MDBH must either grow its revenue base or continue accessing external funding to support its strategy. In short, cash flow is still in the “funding the vision” phase, not yet in a self-sustaining mode.

Competitive Edge

Competitive Edge MDBH’s edge lies in its integrated, niche platform: a broker-dealer focused on early public listings, a sophisticated IP and legal arm (PatentVest), and direct involvement in deep‑tech development (Invizyne). This combination—capital markets, intellectual property strategy, and hands‑on company building—creates a differentiated offering in the capital markets space. The specialization in deep technology and patent-heavy businesses is a clear focus, and the track record of helping build technology leaders via PatentVest adds credibility. The main competitive risks are scale and concentration: the model depends on successfully originating, nurturing, and listing a relatively small number of high-impact “Big Idea” companies, in a market where investor appetite for early-stage, pre‑revenue listings can be cyclical and sensitive to sentiment.

Innovation and R&D

Innovation and R&D Innovation is at the core of MDBH’s identity. Rather than traditional R&D labs, its “research and development” is expressed through platform design and subsidiary capabilities: PatentVest’s proprietary global patent analytics, Invizyne’s enzyme-based biomanufacturing technology, and the public venture structure itself. The planned spin-off of PatentVest and the IPO of Invizyne are part of a broader innovation roadmap to surface value from internal platforms and portfolio companies. This approach offers substantial upside if their technologies and IP strategies gain traction, but it also raises execution risk: value realization depends on successful technology commercialization, IP defensibility, and receptive public markets for early-stage science-driven businesses.

Summary

MDBH is an early-stage, innovation-centric capital markets platform with a very small financial footprint but an ambitious strategy. The core story is not current revenue or cash flow strength—it is the attempt to reinvent how deep‑tech ventures are financed and brought public, using a tightly integrated ecosystem around IP and technology development. The strengths are clear differentiation, domain expertise in patents and deep tech, and the potential leverage from successful IPOs and spin‑offs. The key vulnerabilities are small scale, ongoing cash burn, dependence on a narrow set of ventures and market windows, and the inherent uncertainty of early-stage technology commercialization. MDBH today looks more like a venture-style, platform-building story than a mature financial services firm, with considerable potential but equally meaningful execution and funding risks.

NEWS

November 20, 2025 · 4:05 PM UTC

MDB Capital Holdings Provides Third Quarter 2025 Update

Read more

November 11, 2025 · 9:00 AM UTC

MDB Capital Holdings to Host Third Quarter 2025 Update Conference Call on Thursday November 20, 2025, at 4:30 p.m. Eastern Time

Read more

October 28, 2025 · 1:50 PM UTC

New PatentVest Pulse Report Maps the Competitive and IP Landscape of the $133B Cardiac Diagnostics Market

Read more

October 6, 2025 · 12:30 PM UTC

MDB Capital Holdings, LLC to Present at the LD Micro Main Event XIX

Read more

October 6, 2025 · 12:34 AM UTC

LD Micro Celebrates the 2,000th Company: MDB Capital Holdings (MDBH)

Read more